IRLAB has carried out a directed issue of SEK 70 million and resolves on a rights issue of approximately SEK 145 million
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, UNITED KINGDOM, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL PURSUANT TO APPLICABLE RULES OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. The board of directors of IRLAB Therapeutics AB (publ) (the “Company” or “IRLAB”) has, based on the authorization granted by the annual general meeting on 25 April 2019, resolved to carry out a directed issue of new shares of series A of approximately SEK 70 million to